Aviva’s Krystal Biotech KRYS Stock Holding History

Aviva’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$504K	Sell	1,355 -336	-20%	-$100K	﹤0.01%	695
2026 Q1	$437K	Sell	1,691 -537	-24%	-$143K	﹤0.01%	752
2025 Q4	$549K	Sell	2,228 -1,003	-31%	-$211K	﹤0.01%	710
2025 Q3	$570K	Sell	3,231 -344	-10%	-$51.5K	﹤0.01%	681
2025 Q2	$491K	Buy	3,575 +319	+10%	+$46.9K	﹤0.01%	746
2025 Q1	$587K	Buy	+3,256	New	+$548K	﹤0.01%	728
2021 Q2	–	Sell	-17,198	Closed	-$1.32M	–	923
2021 Q1	$1.32M	Sell	17,198 -11,896	-41%	-$865K	0.01%	745
2020 Q4	$1.75M	Sell	29,094 -23,584	-45%	-$1.18M	0.01%	709
2020 Q3	$2.27M	Sell	52,678 -2,621	-5%	-$114K	0.01%	714
2020 Q2	$2.29M	Sell	55,299 -37,644	-41%	-$1.81M	0.01%	704
2020 Q1	$4.02M	Buy	+92,943	New	+$4.86M	0.03%	461

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Aviva's KRYS Position: Q2 2026 in Review

Aviva reduced its Krystal Biotech (KRYS) stake by 20% in Q2 2026, selling an estimated $100K and leaving 1,355 shares worth $504K. The position accounts for ﹤0.01% of the portfolio, ranked #695.

Aviva first reported a position in KRYS in Q1 2020 and has held it in 11 quarters since. The position peaked at $4.02M in Q1 2020. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Aviva held 1,355 shares of Krystal Biotech worth $504K as of Q2 2026.
Aviva sold 336 Krystal Biotech shares in Q2 2026, an estimated $100K.
Krystal Biotech made up ﹤0.01% of Aviva's portfolio in Q2 2026, its #695 holding.
Aviva first reported a position in Krystal Biotech in Q1 2020 and has held it in 11 quarters since.
Aviva's Krystal Biotech position peaked at $4.02M in Q1 2020.
424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.